Molecular imaging by MRI

Current Cardiology Reports

Volumn 8, Issue 1, 2006, Pages 65-69

  Winter, Patrick M ^b   Caruthers, Shelton D ^b   Wickline, Samuel A ^b   Lanza, Gregory M ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FIBRIN; GADOLINIUM PENTETATE; THROMBOPLASTIN;

ANGIOGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; DIAGNOSTIC ACCURACY; DRUG DELIVERY SYSTEM; IMAGE ANALYSIS; LIPID STORAGE; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; QUANTITATIVE ANALYSIS; RESTENOSIS; REVIEW; SIGNAL NOISE RATIO;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIFIBRINOLYTIC AGENTS; ATHEROSCLEROSIS; CONTRAST MEDIA; DOXORUBICIN; DRUG CARRIERS; FIBRIN; HUMANS; MAGNETIC RESONANCE IMAGING; NANOSTRUCTURES; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33645047422     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-006-0013-2     Document Type: Review

References (23)

1. Naghavi M, Libby P, Falk E, et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664-1672.
2. Lanza GM, Wallace KD, Scott MJ, et al.: A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 1996, 94:3334-3340.
3. Morawski AM, Winter PM, Crowder KC, et al.: Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med 2004, 51:480-486.
4. Delikatny EJ, Poptani H: MR techniques for in vivo molecular and cellular imaging. Radiol Clin North Am 2005, 43:205-220.
5. Mikawa M, Kato H, Okumura M, et al.: Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug Chem 2001, 12:510-514.
6. Winter PM, Caruthers SD, Yu X, et al.: Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med 2003, 50:411-416.
7. Tenaglia AN, Peters KG, Sketch MH, Jr., Annex BH: Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J 1998, 135:10-14.
8. Zhang Y, Cliff WJ, Schoefl GI, Higgins G: Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am J Pathol 1993, 143:164-172.
9. Fay WP: Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. Trends Cardiovasc Med 2004, 14:196-202.
10. Constantinides P: Plaque fissuring in human coronary thrombosis. J Atheroscler Res 1966, 6:1-17.
11. Kerr JS, Mousa SA, Slee AM: Alpha(v)beta(3) integrin in angiogenesis and restenosis. Drug News Perspect 2001, 14:143-150.
12. Bishop GG, McPherson JA, Sanders JM, et al.: Selective alpha(v) beta (3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 2001, 103:1906-1911.
13. Corjay MH, Diamond SM, Schlingmann KL, et al.: alphavbeta3, alphavbeta5, and osteopontin are coordinately upregulated at early time points in a rabbit model of neointima formation. J Cell Biochem 1999, 75:492-504.
14. Wickline SA, Lanza GM: Nanotechnology for molecular imaging and targeted therapy. Circulation 2003, 107:1092-1095.
15. Winter PM, Morawski AM, Caruthers SD, et al.: Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v) beta3-integrin-targeted nanoparticles. Circulation 2003, 108:2270-2274.
16. Mitsumori LM, Ricks JL, Rosenfeld ME, et al.: Development of a lipoprotein based molecular imaging MR contrast agent for the noninvasive detection of early atherosclerotic disease. Int J Cardiovasc Imaging 2004, 20:561-567.
17. Frias JC, Williams KJ, Fisher EA, Fayad ZA: Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004, 126:16316-16317.
18. Ojio S, Takatsu H, Tanaka T, et al.: Considerable time from the onset of plaque rupture and/or thrombi until the onset of acute myocardial infarction in humans: coronary angiographic findings within 1 week before the onset of infarction. Circulation 2000, 102:2063-2069.
19. Yu X, Song S-K, Chen J, et al.: High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med 2000, 44:867-872.
20. Flacke S, Fischer S, Scott MJ, et al.: Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001, 104:1280-1285.
21. Winter PM, Shukla HP, Caruthers SD, et al.: Molecular imaging of human thrombus with computed tomography. Acad Radiol 2005, 12(Suppl 1):S9-S13.
22. Sirol M, Aguinaldo JG, Graham PB, et al.: Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis 2005, 182:79-85.
23. Lanza GM, Yu X, Winter PM, et al.: Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002, 106:2842-2847.